These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 32452167

  • 1. Comparison of safety, efficacy and cost between oral pulse cyclophosphamide versus intravenous cyclophosphamide pulse therapy in severe systemic lupus erythematosus.
    Padiyar S, Arya S, Surin A, Viswanath V, Danda D.
    Int J Rheum Dis; 2020 Jun; 23(6):800-804. PubMed ID: 32452167
    [Abstract] [Full Text] [Related]

  • 2. Intravenous cyclophosphamide pulse therapy in Japanese children with systemic lupus erythematosus.
    Igarashi T, Igarashi T, Shimizu A, Itoh Y.
    J Nippon Med Sch; 2013 Jun; 80(5):396-400. PubMed ID: 24189359
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Increase of peripheral T regulatory cells during remission induction with cyclophosphamide in active systemic lupus erythematosus.
    Tselios K, Sarantopoulos A, Gkougkourelas I, Papagianni A, Boura P.
    Int J Rheum Dis; 2014 Sep; 17(7):790-5. PubMed ID: 25430593
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience.
    Mendonca S, Gupta D, Ali S, Gupta P.
    Saudi J Kidney Dis Transpl; 2017 Sep; 28(5):1069-1077. PubMed ID: 28937065
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil.
    Laskari K, Zintzaras E, Tzioufas AG.
    Clin Exp Rheumatol; 2010 Sep; 28(1):83-6. PubMed ID: 20346244
    [Abstract] [Full Text] [Related]

  • 11. Infection in children with lupus nephritis receiving pulse and oral cyclophosphamide therapy.
    Opastirakul S, Chartapisak W.
    Pediatr Nephrol; 2005 Dec; 20(12):1750-5. PubMed ID: 16133037
    [Abstract] [Full Text] [Related]

  • 12. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
    Rathi M, Goyal A, Jaryal A, Sharma A, Gupta PK, Ramachandran R, Kumar V, Kohli HS, Sakhuja V, Jha V, Gupta KL.
    Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
    [Abstract] [Full Text] [Related]

  • 13. Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study.
    Mehra S, Usdadiya JB, Jain VK, Misra DP, Negi VS.
    Rheumatol Int; 2018 Apr; 38(4):557-568. PubMed ID: 29450636
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus.
    Pryor BD, Bologna SG, Kahl LE.
    Arthritis Rheum; 1996 Sep; 39(9):1475-82. PubMed ID: 8814058
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.